Urologist Survey Good for Teleflex, Bad for Axonics

Medtech analysts at Needham & Co. surveyed 25 urologists that reported doing a median of 30 sacral neuromodulation procedures a year. While the survey implications weren't necessarily bad for Axonics, the firm ultimately decided to downgrade its rating on the company's stock from "buy" to "hold", noting that the stock seems fairly valued at this point.